Loading...
XSTO
EGTX
Market cap146mUSD
Jun 05, Last price  
3.93SEK
1D
-2.96%
1Q
-6.65%
Jan 2017
-77.54%
IPO
-68.55%
Name

Egetis Therapeutics AB (publ)

Chart & Performance

D1W1MN
P/E
—
P/S
30.62
EPS
—
Div Yield, %
—
Shrs. gr., 5y
43.78%
Rev. gr., 5y
-11.00%
Revenues
46m
-19.97%
002,66600000013,585,00028,211,00082,562,00040,662,00038,243,00022,500,00057,600,00046,100,000
Net income
-344m
L+5.11%
-559,065-1,345,648-3,800,624-33,246,055-33,857,000-25,549,000-48,420,000-43,836,000-38,223,000-87,935,000-85,003,000-61,429,000-179,121,000-104,730,000-189,500,000-326,900,000-343,600,000
CFO
-228m
L-18.14%
-2,717,199-14,395,782-31,957,000-28,066,000-41,384,000-51,153,000-36,115,000-86,551,000-80,310,000-62,641,000-134,639,000-130,110,000-173,500,000-278,400,000-227,900,000
Earnings
Aug 20, 2025

Profile

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
URL
https://www.egetis.com/
IPO date
Apr 07, 2011
Employees
23
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
46,100
-19.97%
57,600
156.00%
22,500
-41.17%
Cost of revenue
373,100
204,500
278,900
Unusual Expense (Income)
NOPBT
(327,000)
(146,900)
(256,400)
NOPBT Margin
Operating Taxes
300
100
(4,300)
Tax Rate
NOPAT
(327,300)
(147,000)
(252,100)
Net income
(343,600)
5.11%
(326,900)
72.51%
(189,500)
80.94%
Dividends
Dividend yield
Proceeds from repurchase of equity
300,000
381,900
164,800
BB yield
-12.21%
-26.32%
-11.95%
Debt
Debt current
30,100
7,400
1,600
Long-term debt
84,100
110,000
3,800
Deferred revenue
Other long-term liabilities
10,600
5,100
4,400
Net debt
(236,800)
(186,700)
(123,100)
Cash flow
Cash from operating activities
(227,900)
(278,400)
(173,500)
CAPEX
Cash from investing activities
(1,200)
(100)
(1,700)
Cash from financing activities
270,900
458,900
155,700
FCF
(325,500)
(148,700)
(250,526)
Balance
Cash
351,000
303,300
127,700
Long term investments
800
800
Excess cash
348,695
301,220
127,375
Stockholders' equity
(1,589,700)
(1,234,400)
(922,200)
Invested Capital
2,207,300
1,898,100
1,435,500
ROIC
ROCE
EV
Common stock shares outstanding
350,875
260,011
194,238
Price
7.00
25.45%
5.58
-21.41%
7.10
5.81%
Market cap
2,456,128
69.29%
1,450,864
5.20%
1,379,091
14.24%
EV
2,219,328
1,264,164
1,255,991
EBITDA
(327,000)
(143,300)
(253,700)
EV/EBITDA
Interest
25,900
4,100
100
Interest/NOPBT